FluoroPharma Medical, Inc.
FPMI
$0.0001
$0.000.00%
OTC PK
| 12/31/2016 | 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.61% | -30.73% | -27.01% | -27.45% | -7.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.58% | -59.27% | -3.66% | -20.79% | -34.15% |
| Operating Income | 37.58% | 59.27% | 3.66% | 20.79% | 34.15% |
| Income Before Tax | 89.96% | 266.16% | 48.59% | -173.92% | -1,249.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 89.96% | 266.16% | 48.59% | -173.92% | -1,249.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.96% | 266.16% | 48.59% | -173.92% | -1,249.18% |
| EBIT | 37.58% | 59.27% | 3.66% | 20.79% | 34.15% |
| EBITDA | 38.06% | 60.12% | 3.62% | 20.89% | 34.36% |
| EPS Basic | 83.41% | 676.92% | 51.50% | -110.61% | -3,616.67% |
| Normalized Basic EPS | 91.61% | 154.55% | 53.47% | 10.66% | -1,343.48% |
| EPS Diluted | 83.41% | 353.85% | 51.50% | -110.61% | -3,616.67% |
| Normalized Diluted EPS | 91.61% | 13.64% | 53.47% | 10.66% | -1,343.48% |
| Average Basic Shares Outstanding | 7.52% | 12.94% | 13.57% | 13.12% | 8.35% |
| Average Diluted Shares Outstanding | 7.52% | 155.43% | 13.57% | 13.12% | 8.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |